s
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
24-01-2024, 09:46
SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ — Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in microbiome therapeutic development announced on January 18th that a poster was presented on the positive topline results from the phase 2 clinical trial (NCT05419362) in gastric cancer of its microbiome immunotherapy, GEN-001 at the American Society […] L'articolo Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI proviene da La Ragione.
CONTINUA A LEGGERE
12
0
0
Guarda anche
La Ragione
22:12
Le Pen: “La marea cresce, la nostra vittoria è solo rimandata”
La Ragione
19:43
Keys si fa male e si ritira, Paolini ai quarti di Wimbledon
La Ragione
19:34